• Anticancer research · Apr 2015

    Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy.

    • Yasuo Sakamoto, Yuji Miyamoto, Toru Beppu, Hidetoshi Nitta, Katsunori Imai, Hiromitsu Hayashi, Yoshifumi Baba, Naoya Yoshida, Akira Chikamoto, and Hideo Baba.
    • Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan Department of Multidisciplinary Treatment for Gastroenterological Cancer, Kumamoto University Hospital, Kumamoto, Japan.
    • Anticancer Res. 2015 Apr 1; 35 (4): 2359-68.

    Background/AimThe prognostic value of tumor markers remains unclear in patients with colorectal liver metastases (CRLM) who undergo hepatectomy following chemotherapy. The aim of the present study was to identify prognostic factors associated with recurrence and survival in such patients.Patients And MethodsBetween 2005 and 2012, 62 patients with initially unresectable or marginally unresectable CRLM who underwent hepatectomy following chemotherapy were enrolled. A Cox proportional hazards model was used to identify the prognostic factors.ResultsMultivariate analysis indicated that a high level of carbohydrate antigen 19-9 (CA19-9) in serum post-chemotherapy was significant factor, predictive of poor overall survival [Hazard Ratio (HR)=4.46, 95% Confidence Interval (CI)=1.68-11.8; p=0.003] and marginally significant regarding poorer relapse-free survival (HR=2.11, 95% CI=0.99-4.47; p=0.050). Non-response to preoperative chemotherapy was a significant prognostic factor regarding shorter relapse-free (HR=2.18, 95% CI=1.10-4.33; p=0.026) and overall survival (HR=3.14, 95% CI=1.22-8.08; p=0.018). High levels of carcinoembryonic antigen CEA in serum post-chemotherapy (HR=3.08, 95% CI=1.13-8.39; p=0.028) and the absence of adjuvant chemotherapy (HR=2.27, 95% CI=1.17-4.41; p=0.016) were independent risk factors for recurrence.ConclusionMeasurement of both CEA and CA19-9 level is strongly recommended for patients with CRLM treated with preoperative chemotherapy followed by hepatectomy because normalization of serum CEA and CA19-9 levels after chemotherapy will demonstrate a good prognosis after curative hepatectomy.Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…